News25/Ratings0
News · 26 weeks28+22%
2025-10-262026-04-19
Mix2190d
- Insider17(81%)
- SEC Filings2(10%)
- Other2(10%)
Latest news
25 items- INSIDERAmendment: SEC Form 3 filed by new insider Chen Hong-Jung3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 4 filed by Lin Peter Kuan-How4 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Jan Chen-Huan3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Tsai Hsien-Shu3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Lin Peter Kuan-How3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Chen Hung-Wen3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Chu Yi-An3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Chen Yi-Kuei3/A - Apollomics Inc. (0001944885) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Huang Ya-Chi3/A - Apollomics Inc. (0001944885) (Issuer)
- SECSEC Form 6-K filed by Apollomics Inc.6-K - Apollomics Inc. (0001944885) (Filer)
- PRApollomics Inc. Announces $2.0 Million Bridge FinancingFOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the "Note") with Mr. Hung-Wen (Howard) Chen, the Company's Chairman and Chief Executive Officer, on March 30, 2026. The $2.0 million in proceeds from the Note are intended to provide the Company with necessary working capital to support clinical development programs and general corporate operations. The Note is an unsecured obligation of the Company and carries a 0% interest rate. Under the terms of the agreement, the principal amount will automatically convert into equity secu
- INSIDERSEC Form 3 filed by new insider Chen Hung-Wen3 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chen Hong-Jung3 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chu Yi-An3 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 3 filed by new insider Huang Ya-Chi3 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tsai Hsien-Shu3 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jan Chen-Huan3 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chen Yi-Kuei3 - Apollomics Inc. (0001944885) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lin Peter Kuan-How3 - Apollomics Inc. (0001944885) (Issuer)
- SECSEC Form F-3 filed by Apollomics Inc.F-3 - Apollomics Inc. (0001944885) (Filer)
- SECSEC Form S-8 filed by Apollomics Inc.S-8 - Apollomics Inc. (0001944885) (Filer)
- SECSEC Form 6-K filed by Apollomics Inc.6-K - Apollomics Inc. (0001944885) (Filer)
- PRApollomics Reports First Half 2025 Financial ResultsFOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2.1 million, compared to $9.8 million as of December 31, 2024. Based on current projections, the Company believes its cash position is sufficient to fund planned operations into the third quarter of
- SECSEC Form 6-K filed by Apollomics Inc.6-K - Apollomics Inc. (0001944885) (Filer)
- PRApollomics Announces Settlement of Cayman LitigationFOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (NASDAQ:APLM) announced today entering into a settlement agreement (the "Settlement Agreement" or the "Agreement") with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, "TWVC"), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the "Cayman Litigation"). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company's merger with Maxp